251 related articles for article (PubMed ID: 36781621)
1. Neoadjuvant Therapy in Melanoma: Where Are We Now?
Saad M; Tarhini AA
Curr Oncol Rep; 2023 Apr; 25(4):325-339. PubMed ID: 36781621
[TBL] [Abstract][Full Text] [Related]
2. Clinical updates in neoadjuvant immunotherapy for melanoma before surgery.
Saad M; Castellano E; Tarhini AA
Expert Rev Clin Immunol; 2023 Aug; ():1-17. PubMed ID: 37578289
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant immunotherapy of melanoma and development of new approaches using the neoadjuvant approach.
Davar D; Tarhini AA; Kirkwood JM
Clin Dermatol; 2013; 31(3):237-50. PubMed ID: 23608443
[TBL] [Abstract][Full Text] [Related]
4. Treatment of Stage III Resectable Melanoma-Adjuvant and Neoadjuvant Approaches.
Tarhini AA; Castellano E; Eljilany I
Cancer J; 2024 Mar-Apr 01; 30(2):54-70. PubMed ID: 38527258
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant Immunotherapy for Locally Advanced Melanoma.
Pelster MS; Amaria RN
Curr Treat Options Oncol; 2020 Feb; 21(2):10. PubMed ID: 32025932
[TBL] [Abstract][Full Text] [Related]
6. The Role of Neoadjuvant Therapy in Melanoma.
Kelly ZR; Gorantla VC; Davar D
Curr Oncol Rep; 2020 Jun; 22(8):80. PubMed ID: 32601947
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant Immune Checkpoint Inhibitor Therapy in Melanoma: Efficacy, Safety and Timing.
van Akkooi ACJ; Zijlker LP; Wouters MWJM
BioDrugs; 2022 May; 36(3):373-380. PubMed ID: 35397089
[TBL] [Abstract][Full Text] [Related]
8. Rapidly Evolving Pre- and Post-surgical Systemic Treatment of Melanoma.
Augustin RC; Luke JJ
Am J Clin Dermatol; 2024 May; 25(3):421-434. PubMed ID: 38409643
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant Checkpoint Immunotherapy and Melanoma: The Time Is Now.
Long GV; Menzies AM; Scolyer RA
J Clin Oncol; 2023 Jun; 41(17):3236-3248. PubMed ID: 37104746
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.
Amaria RN; Prieto PA; Tetzlaff MT; Reuben A; Andrews MC; Ross MI; Glitza IC; Cormier J; Hwu WJ; Tawbi HA; Patel SP; Lee JE; Gershenwald JE; Spencer CN; Gopalakrishnan V; Bassett R; Simpson L; Mouton R; Hudgens CW; Zhao L; Zhu H; Cooper ZA; Wani K; Lazar A; Hwu P; Diab A; Wong MK; McQuade JL; Royal R; Lucci A; Burton EM; Reddy S; Sharma P; Allison J; Futreal PA; Woodman SE; Davies MA; Wargo JA
Lancet Oncol; 2018 Feb; 19(2):181-193. PubMed ID: 29361468
[TBL] [Abstract][Full Text] [Related]
11. Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in
White MG; Szczepaniak Sloane R; Witt RG; Reuben A; Gaudreau PO; Andrews MC; Feng N; Johnson S; Class CA; Bristow C; Wani K; Hudgens C; Nezi L; Manzo T; De Macedo MP; Hu J; Davis R; Jiang H; Prieto P; Burton E; Hwu P; Tawbi H; Gershenwald J; Lazar AJ; Tetzlaff MT; Overwijk W; Woodman SE; Cooper ZA; Marszalek JR; Davies MA; Heffernan TP; Wargo JA
Oncoimmunology; 2021; 10(1):1992880. PubMed ID: 34777916
[TBL] [Abstract][Full Text] [Related]
12. The Role of BRAF-Targeted Therapy for Advanced Melanoma in the Immunotherapy Era.
Vanella V; Festino L; Trojaniello C; Vitale MG; Sorrentino A; Paone M; Ascierto PA
Curr Oncol Rep; 2019 Jul; 21(9):76. PubMed ID: 31359162
[TBL] [Abstract][Full Text] [Related]
13. BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma: a potential neoadjuvant strategy.
Sloot S; Zager JS; Kudchadkar RR; Messina JL; Benedict JJ; Gonzalez RJ; DeConti R; Turner LM; McCardle T; Smalley KS; Weber JS; Sondak VK; Gibney GT
Melanoma Res; 2016 Feb; 26(1):83-7. PubMed ID: 26731560
[TBL] [Abstract][Full Text] [Related]
14. Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC).
Menzies AM; Amaria RN; Rozeman EA; Huang AC; Tetzlaff MT; van de Wiel BA; Lo S; Tarhini AA; Burton EM; Pennington TE; Saw RPM; Xu X; Karakousis GC; Ascierto PA; Spillane AJ; van Akkooi ACJ; Davies MA; Mitchell TC; Tawbi HA; Scolyer RA; Wargo JA; Blank CU; Long GV
Nat Med; 2021 Feb; 27(2):301-309. PubMed ID: 33558722
[TBL] [Abstract][Full Text] [Related]
15. Update on BRAF and MEK inhibition for treatment of melanoma in metastatic, unresectable, and adjuvant settings.
Broman KK; Dossett LA; Sun J; Eroglu Z; Zager JS
Expert Opin Drug Saf; 2019 May; 18(5):381-392. PubMed ID: 30977681
[TBL] [Abstract][Full Text] [Related]
16. The case for adjuvant BRAF-targeted therapy versus adjuvant anti-PD-1 therapy for patients with resected, high-risk melanoma.
Mooradian MJ; Sullivan RJ
Cancer; 2023 Jul; 129(14):2117-2121. PubMed ID: 37345669
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive Clinical Trial Data Summation for BRAF-MEK Inhibition and Checkpoint Immunotherapy in Metastatic Melanoma.
Luke JJ
Oncologist; 2019 Nov; 24(11):e1197-e1211. PubMed ID: 31064886
[TBL] [Abstract][Full Text] [Related]
18. Targeting BRAF and MEK inhibitors in melanoma in the metastatic, neoadjuvant and adjuvant setting.
Tétu P; Baroudjian B; Lebbe C
Curr Opin Oncol; 2020 Mar; 32(2):85-90. PubMed ID: 31895121
[TBL] [Abstract][Full Text] [Related]
19. Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy.
Rose AAN; Armstrong SM; Hogg D; Butler MO; Saibil SD; Arteaga DP; Pimentel Muniz T; Kelly D; Ghazarian D; King I; Kamil ZS; Ross K; Spreafico A
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33483342
[TBL] [Abstract][Full Text] [Related]
20. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
Hu-Lieskovan S; Mok S; Homet Moreno B; Tsoi J; Robert L; Goedert L; Pinheiro EM; Koya RC; Graeber TG; Comin-Anduix B; Ribas A
Sci Transl Med; 2015 Mar; 7(279):279ra41. PubMed ID: 25787767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
